NasdaqGS:ERASBiotechs
Is Erasca (ERAS) Stock Trading At A Premium After New Trial Data?
Erasca stock has delivered a very large 1 year return, yet its valuation checks and current pricing invite the question of how much of the story is already reflected in the share price.
Over the past year, Erasca has returned about 12.8x, a move that puts extra focus on whether recent gains leave much room for disappointment.
Updated preliminary Phase 1 data for ERAS-0015 and plans for registration-enabling trials can support high growth expectations. At the same time, the upsized public...